JPM 2019 Day 3: Becton Dickinson

The third day of the 2019 J.P. Morgan Healthcare conference included a presentation from Becton Dickinson, which is the final diabetes-related presentation of the conference. BD senior management briefly discussed their T2DM patch pump, called Swatch, which has already been filed with FDA with a limited launch scheduled before YE 2019. Below, FENIX provides key takeaways from the BD presentation and thoughts on the future T2DM pump market including a competitor comparison table. In case you missed it, here are links to FENIX’s Day 1 and Day 2 JPM 2019 insights. Becton Dickinson In response to an analyst’s question, BD management……

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.